44660
document
Final analysis of the UKLG LY02 trial comparing 6-8 cycles of CHOP with 3 cycles of CHOP followed by a BEAM autograft in patients < 65 years with poor prognosis histologically aggressive NHL . This trial involved 457 patients and sought to assess the value of early intensification with autologous transplantation in patients with poor prognosis histologically aggressive non-Hodgkin lymphoma ( NHL ) showing a response to initial CHOP ( cyclophosphamide , doxorubicin , vincristine , prednisolone ) chemotherapy . Randomization was made at the time of diagnosis with 223 assigned to continuing CHOP and 234 to 3 cycles of CHOP followed by a BEAM ( carmustine , etoposide , cytarabine , melphalan ) autograft . Analysis was on an intention to treat basis . After the initial three cycles of CHOP 19 % of the whole group were in complete response ( CR ) and 53 % in partial remission ( PR ) . At the end of treatment 86 % of patients in the CHOP arm had responded with 58 % in CR . In the high-dose therapy arm the overall response rate was 83 % with 64 % in CR ( difference between arms not significant ) . The progression-free survival ( PFS ) and overall survival at 5 years for the continuing CHOP arm were 38 % and 50 % respectively , and for the autograft arm were 44 % and 50 % ( differences not significant ) . Of the patients who attained CR and subsequently relapsed , there were no long-term survivors in the autograft recipients compared to 46 % of the continuing CHOP recipients ( P = 0.0008 ) . In conclusion , no survival benefit was demonstrated for an early autograft in first response .
44661
Intervention_Pharmacological
CHOP
44662
Intervention_Pharmacological
CHOP
44663
Intervention_Pharmacological
BEAM autograft
44664
Intervention_Pharmacological
CHOP ( cyclophosphamide , doxorubicin , vincristine , prednisolone ) chemotherapy
44665
Intervention_Pharmacological
CHOP
44666
Intervention_Pharmacological
CHOP
44667
Intervention_Pharmacological
BEAM ( carmustine , etoposide , cytarabine , melphalan ) autograft
44668
Intervention_Pharmacological
CHOP
44669
Intervention_Pharmacological
CHOP
44670
Intervention_Pharmacological
CHOP
44671
Outcome_Physical
complete response ( CR )
44672
Outcome_Physical
partial remission ( PR ) .
44673
Outcome_Mortality
the overall response rate
44674
Outcome_Mortality
The progression-free survival ( PFS ) and overall survival at 5 years
44675
Outcome_Physical
relapsed
44676
Outcome_Mortality
long-term survivors
44677
Participant_Age
< 65 years
44678
Participant_Condition
NHL
44679
Participant_Sample-size
457
44680
Participant_Condition
non-Hodgkin lymphoma